This e-learning course will help you, as a physician or nurse, better understand skin reactions to targeted therapy in GI and liver cancers. The course will help you prevent, diagnose and manage these dermatologic adverse events and involve a multidisciplinary team to optimise patient care.

This e-learning course discusses the impact of TRIBE-2, Re-ARRANGE and FOxTROT data in colorectal cancer (CRC) on sequential clinical practice. Key clinical questions will be addressed, including;

  • Can we use a flexible dosing approach for regorafenib to improve the safety profile without affecting the efficacy in refractory metastatic colorectal cancer (mCRC)?
  • What is the best sequential therapy strategy in mCRC: a classic first and second line regimen or upfront higher regimen followed by the same regimen?
  • Is neoadjuvant chemotherapy effective in the treatment of CRC?

This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).

This e-learning course will improve the benefits of interactions between nurses and patients with colorectal cancer. The same principles can be more widely applied to interactions with patients with any other cancer. GUIDE’s five letters each represent a crucial step in conversations with patients:

  • Gain insight into the goals of treatment and care
  • Understand the gaps in the patient’s knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient
  • This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).

The length of treatment for colorectal cancer (CRC) patients in the adjuvant setting is a controversial topic. Recent studies have compared the outcomes for patients receiving adjuvant therapy with FOLFOX or CAPOX for 3 or for 6 months. What should be the recommended length of treatment for CRC patients in the adjuvant setting? Do recent data support a 3-month or 6-month duration? The following e-learning course includes expert opinions on the latest answers to these important questions.

This e-learning demonstrates what you need to explain to your patients requiring 3rd-line treatment of mCRC and how to confidently communicate these messages for an optimal physician-patient interaction.

Ultimately, success is both parties being satisfied with the decision-making process and with the decision that is made.

Experts provide opposing perspectives on the management of later-line CRC on treatment sequencing and flexible dosing of regorafenib.

Note that the views presented do not reflect the Experts’ own opinions but are intended to represent opposing perspectives on the topic of discussion.

EACCME Accreditation

COR2ED Checkpoint, made available on and organized by COR2ED, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Information on the process to convert EACCME credit to AMA credit can be found at